Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 179
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data
Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts
Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast
BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
MYND Life Sciences Announces $3.5 Million Share Offering
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial...
COMPASS Pathways partners with One Mind to fund Rising Star Awards...
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application...
Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural...
Psychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse...
MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results...
Numinus Wellness Inc. Reports Q2 2022 Results
PT313 – Christine Calvert, LCDC – Holotropic Breathwork, Ethics, and Dying...
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial...
Load more